ResMed (NYSE:RMD) traded today at a new 52-week high of $51.22. This new high was reached on below average trading volume as 526,000 shares traded hands, while the average 30-day volume is approximately 1.1 million shares.
Based on a current price of $51.03, ResMed is currently 8.2% above its average consensus analyst price target of $46.86. ResMed shares have support at the 50-day moving average (MA) of $45.65 and additional support at the 200-day MA of $41.77.
In the past 52 weeks, ResMed share prices have been bracketed by a low of $29.82 and a high of $51.22 and are now at $51.03, 71% above that low price. Over the past week, the 200-day moving average (MA) has gone up 1.1% while the 50-day MA has advanced 1.3%.
ResMed Inc. develops, manufactures, and markets medical equipment for the treatment of sleep disordered breathing. The Company sells diagnostic and treatment devices in various countries through its subsidiaries and independent distributors.